Review the bio-based chemicals business to enhance profitability
First written in FY2016. 11 of 33 entries say "Advanced", first in FY2018-Q3. Latest entry: 2026-08-05.
No other company in this theme has enough history to compare yet.
- 2026-08-05AdvancedEarnings
「この結果、国内 その他事業の売上収益は59億７千万円（前年同期比110.5％）、事業利益は７億６千８百万円（前年同期比160.4％）と、増収増益となりました。」
国内その他事業が増収増益となり、収益力改善の進展が示された。 - FY2026AdvancedAnnual report
「Accordingly, Domestic Other Business posted revenue of ¥21.765 billion, or 100.9% of the same period of the previous year, and business profit of ¥1.627 billion, or 138.8%, resulting in higher revenue and higher profit.」
Domestic Other Business posted revenue at 100.9% and business profit at 138.8%, indicating an improvement in profitability from the previous fiscal year's lower revenue and lower profit. - FY2026-H1Lower revenue, higher profitAnnual report
「Accordingly, Domestic Other Business posted revenue of ¥10.938 billion, or 99.1% of the same period of the previous year, and business profit of ¥859 million, or 112.6%, resulting in lower revenue and higher profit.」
Revenue at Domestic Other Business fell below the same period of the previous year, while business profit exceeded it, indicating an improvement in profitability. - FY2025Impairment loss recognized in the chemicals business due to delays in starting operations at the facility.Annual report
「Business profit deteriorated because the start of operations at the new manufacturing building was delayed and issues arose concerning the stable supply of some products.」
Business profit deteriorated due to the delayed start of operations at the new manufacturing building at the Kamogawa Plant and issues with the stable supply of some products, resulting in recognition of an impairment loss of ¥1.702 billion in Domestic Other Business. - FY2025-H1AdvancedAnnual report
「Accordingly, Domestic Other Business posted revenue of ¥11.033 billion, or 103.1% of the same period of the previous year, and business profit of ¥762 million, or 149.7%, resulting in higher revenue and higher profit.」
Domestic Other Business posted higher revenue and higher profit, with revenue at 103.1% and business profit at 149.7%, indicating an improvement in profitability from the previous fiscal year's lower revenue and lower profit. - FY2024Lower revenue and earnings continued, with the decline in earnings wideningAnnual report
「Accordingly, Domestic Other Business posted revenue of ¥21.22 billion, or 96.9% of the same period of the previous year, and business profit of ¥919 million, or 51.0%, resulting in lower revenue and lower profit.」
Domestic Other Business continued to post lower revenue and lower profit, with revenue at 96.9% and business profit at 51.0% of the same period of the previous year. Compared with the cumulative third-quarter figures of 97.3% for revenue and 53.2% for business profit, the declines in both revenue and profit widened for the full year. - FY2024-Q3Lower revenue and lower profit continued, and the decline in revenue widened.Annual report
「Accordingly, Domestic Other Business posted revenue of ¥16.125 billion, or 97.3% of the same period of the previous year, and business profit of ¥814 million, or 53.2%, resulting in lower revenue and lower profit.」
Domestic Other Business continued to post lower revenue and lower profit, with revenue at 97.3% and business profit at 53.2% of the same period of the previous year. Compared with the previous quarter's revenue at 98.9% and business profit at 52.7%, the decline in revenue widened. - FY2024-Q2Lower revenue and profit continuedAnnual report
「Accordingly, Domestic Other Business posted revenue of ¥10.702 billion, or 98.9% of the same period of the previous year, and business profit of ¥509 million, or 52.7%, resulting in lower revenue and lower profit.」
Domestic Other Business posted lower revenue and lower profit, with revenue at 98.9% and business profit at 52.7%. Sales of enzymes for clinical diagnostics and hyaluronic acid fell below the same period of the previous year, indicating continued deterioration in profitability following the previous quarter. - FY2024-Q1Revenue and Profit DeclineAnnual report
「Accordingly, Domestic Other Business posted revenue of ¥5.162 billion, or 95.5% of the same period of the previous year, and business profit of ¥258 million, or 54.0%, resulting in lower revenue and lower profit.」
Domestic Other Business posted lower revenue and lower profit, with revenue at 95.5% and business profit at 54.0%, due to lower revenue from enzymes for clinical diagnostics and hyaluronic acid. - FY2023Higher revenue, lower profitAnnual report
「Accordingly, Domestic Other Business posted revenue of ¥21.893 billion, or 101.2% of the same period of the previous year, and business profit of ¥1.801 billion, or 96.3%, resulting in higher revenue and lower profit.」
Revenue rose as sales of enzymes for clinical diagnostics and hyaluronic acid grew, while business profit fell below the same period of the previous year. - FY2023-Q3AdvancedAnnual report
「Accordingly, Domestic Other Business posted revenue of ¥16.572 billion, or 102.4% of the same period of the previous year, and business profit of ¥1.531 billion, or 105.6%, resulting in higher revenue and higher profit.」
Growth in enzymes for clinical diagnostics drove Domestic Other Business to higher revenue and higher profit, with revenue at 102.4% and business profit at 105.6%. - FY2023-Q2AdvancedAnnual report
「Accordingly, Domestic Other Business posted revenue of ¥10.82 billion, or 102.0% of the same period of the previous year, and business profit of ¥966 million, or 110.2%, resulting in higher revenue and higher profit.」
Domestic Other Business continued to post higher revenue and higher profit, with revenue at 102.0% and business profit at 110.2%. - FY2023-Q1AdvancedAnnual report
「Accordingly, Domestic Other Business posted revenue of ¥5.46 billion, or 102.9% of the same period of the previous year, and business profit of ¥478 million, or 128.0%, resulting in higher revenue and higher profit.」
Growth in enzymes for clinical diagnostics drove Domestic Other Business to higher revenue and higher profit, with revenue at 102.9% and business profit at 128.0%. - FY2022-Q3RestatedAnnual report
「Accordingly, Domestic Other Business posted revenue of ¥16.179 billion, or 101.2% of the same period of the previous year, and business profit of ¥1.449 billion, or 98.9%, resulting in higher revenue and lower profit.」
Revenue at Domestic Other Business exceeded the same period of the previous year, while business profit fell below it, and higher revenue with lower profit continued. - FY2022-Q2RestatedAnnual report
「Accordingly, Domestic Other Business posted revenue of ¥10.606 billion, or 101.3% of the same period of the previous year, and business profit of ¥876 million, or 91.5%, resulting in higher revenue and lower profit.」
Domestic Other Business posted higher revenue due to growth in clinical diagnostic reagents, while business profit fell below the same period of the previous year, and higher revenue with lower profit continued. - FY2022-Q1Higher revenue, lower profitAnnual report
「Accordingly, Domestic Other Business posted revenue of ¥5.253 billion, or 101.2% of the same period of the previous year, and business profit of ¥373 million, or 72.9%, resulting in higher revenue and lower profit.」
Revenue rose to 101.2% of the same period of the previous year due to growth in clinical diagnostic reagents, hygiene testing reagents and the transportation business, while business profit was 72.9%, resulting in higher revenue and lower profit. - FY2021AdvancedAnnual report
「Accordingly, Domestic Other Business posted revenue of ¥21.86 billion, or 99.3% of the previous fiscal year, and business profit of ¥1.915 billion, or 114.1%, resulting in lower revenue and higher profit.」
Although revenue at Domestic Other Business fell below the previous fiscal year, business profit was 114.1% of the previous fiscal year. For the full year, results changed from the lower revenue and lower profit seen through the immediately preceding quarter to lower revenue and higher profit. - FY2021-Q3Continued declines in revenue and profit, but the declines narrowedAnnual report
「Accordingly, Domestic Other Business posted revenue of ¥15.980 billion, or 99.5% of the same period of the previous year, and operating profit of ¥1.307 billion, or 95.2%, resulting in lower revenue and lower profit.」
Although hygiene testing reagents grew, Domestic Other Business posted lower revenue and lower profit due to lower revenue from clinical diagnostic reagents and the transportation business. The declines narrowed from the cumulative second-quarter year-on-year levels of 98.5% for revenue and 90.8% for operating profit. - FY2021-Q2RestatedAnnual report
「Chemicals and other products exceeded the revenue of the same period of the previous year, as growth in hygiene testing reagents offset the declines in clinical diagnostic reagents and hyaluronic acid. The transportation business fell below the same period of the previous year. As a result, the segment as a whole fell below the revenue of the same period of the previous year.」
Although hygiene testing reagents grew, Domestic Other Business posted lower revenue and lower profit, with revenue at 98.5% and operating profit at 90.8%, due to lower revenue from clinical diagnostic reagents, hyaluronic acid and the transportation business. - FY2021-Q1Domestic Other Business posted lower revenue and lower profit despite growth in hygiene testing reagents.Annual report
「Chemicals and other products exceeded the revenue of the same period of the previous year, as growth in hygiene testing reagents offset the declines in clinical diagnostic reagents and hyaluronic acid. The transportation business fell below the same period of the previous year. As a result, revenue for the segment as a whole fell below the same period of the previous year.」
Although hygiene testing reagents grew, Domestic Other Business posted lower revenue and lower profit, with revenue at 96.6% and operating profit at 82.2%, due to lower revenue from clinical diagnostic reagents, hyaluronic acid and the transportation business. - FY2020-Q3RestatedAnnual report
「Chemicals and other products fell below the same period of the previous year, as hyaluronic acid performed well but clinical diagnostic reagents were weak, with the withdrawal from the alginate business also having an impact. As a result, revenue for the segment as a whole fell below the same period of the previous year. Accordingly, Domestic Other Business posted revenue of ¥16.056 billion, or 98.9% of the same period of the previous year, and operating profit of ¥1.373 billion, or 103.8%, resulting in lower revenue and higher profit.」
Hyaluronic acid performed well, but revenue fell due to weak clinical diagnostic reagents and the impact of the withdrawal from the alginate business. Meanwhile, Domestic Other Business continued to post lower revenue and higher profit, with operating profit at 103.8% of the same period of the previous year. - FY2020-Q2Revenue fell and profit rose due to the withdrawal from the alginate business.Annual report
「Hyaluronic acid performed well, but clinical diagnostic reagents were weak, and the withdrawal from the alginate business also affected results, causing revenue to fall below the same period of the previous year. As a result, revenue for the segment as a whole fell below the same period of the previous year. Accordingly, Domestic Other Business posted revenue of ¥10.635 billion, or 98.6% of the same period of the previous year, and operating profit of ¥916 million, or 103.6%, resulting in lower revenue and higher profit.」
Hyaluronic acid performed well, but revenue fell due to weak clinical diagnostic reagents and the impact of the withdrawal from the alginate business. Operating profit, however, was 103.6% of the same period of the previous year. - FY2020-Q1AdvancedAnnual report
「As a result, domestic other businesses posted revenue of ¥5.373 billion, or 103.3% of the prior-year period, and operating profit of ¥503 million, or 135.0%, resulting in higher revenue and higher profit.」
Domestic Other Business continued to post higher revenue and higher operating profit, with revenue at 103.3% and operating profit at 135.0%. - FY2019RestatedAnnual report
「As a result, domestic other businesses posted revenue of ¥21.427 billion, or 101.3% of the prior period, and operating profit of ¥1.773 billion, or 121.0%, resulting in higher revenue and higher profit.」
Contributions from clinical diagnostics, hygiene testing products, hyaluronic acid and the transportation business confirmed full-year higher revenue and higher profit for domestic other businesses. - FY2019-Q3RestatedAnnual report
「As a result, domestic other businesses posted revenue of ¥16.236 billion, or 100.6% of the prior-year period, and operating profit of ¥1.322 billion, or 121.0%, resulting in higher revenue and higher profit.」
Contributions from clinical diagnostics, hygiene testing products and the transportation business resulted in higher revenue and higher profit for domestic other businesses. - FY2019-Q2AdvancedAnnual report
「Clinical diagnostics, hygiene testing products and hyaluronic acid performed well. The transportation business exceeded the prior-year period. As a result, segment-wide sales exceeded the prior-year period. Domestic other businesses posted revenue of ¥10.789 billion, or 100.9% of the prior-year period, and operating profit of ¥884 million, or 121.6%, resulting in higher revenue and higher profit.」
Contributions from clinical diagnostics, hygiene testing products, hyaluronic acid and the transportation business improved domestic other businesses from lower revenue in the first quarter of the prior fiscal year to higher revenue and higher profit. - FY2019-Q1RestatedAnnual report
「Clinical diagnostics and hygiene testing products performed well, but the chemical products business, including hyaluronic acid, was weak. The transportation business exceeded the prior-year period. As a result, segment-wide sales fell below the prior-year period.」
Hygiene testing products and other businesses performed well and the transportation business exceeded the prior-year period, but domestic other businesses posted lower revenue because of weakness in the chemical products business. - FY2018ReframedAnnual report
「In bio-based chemicals, we will improve profitability, focusing on growth in the hygiene testing business.」
The company specified its priority measures, shifting from the previous focus on a business review to improving profitability centered on growth in the hygiene testing business. - FY2018-Q3AdvancedAnnual report
「Clinical diagnostics and hygiene testing products performed well, but the chemical products business, including hyaluronic acid, was weak. The transportation business exceeded the prior-year period. As a result, segment-wide sales exceeded the prior-year period. Domestic other businesses posted revenue of ¥16.137 billion, or 100.4% of the prior-year period, and operating profit of ¥1.093 billion, or 105.3%, resulting in higher revenue and higher profit.」
Although the chemical products business was weak, clinical diagnostics, hygiene testing products and the transportation business contributed, resulting in higher revenue and higher profit for domestic other businesses as a whole. This marked an improvement from the lower revenue reported through the previous quarter. - FY2018-Q2RestatedAnnual report
「Clinical diagnostics performed well, but the chemical products business, including hyaluronic acid, was weak, and sales fell below the prior-year period. As a result, segment-wide sales fell below the prior-year period.」
Domestic other businesses continued to post lower revenue because of weakness in the chemical products business. - FY2018-Q1Chemical products business remained weak, but domestic other businesses posted lower revenue and higher operating profitAnnual report
「Clinical diagnostics performed well, but the chemical products business, including hyaluronic acid, was weak, and sales fell below the prior-year period. As a result, segment-wide sales fell below the prior-year period.」
Domestic other businesses posted lower revenue but higher operating profit because of weakness in the chemical products business. - FY2017RestatedAnnual report
「In bio-based chemicals, we will review the business and improve its profitability.」
The policy of improving profitability through a review of the bio-based chemicals business was reiterated. - FY2016First statedAnnual report
「In bio-based chemicals, we will review the business and improve its profitability.」
The company set out to improve profitability through a business review.